SYAB Stock Overview

Provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. More details

SYAB fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	2/6
Financial Health	4/6
Dividends	0/6

Rewards

Became profitable this year

Risk Analysis

Earnings are forecast to decline by an average of 11.4% per year for the next 3 years

Large one-off items impacting financial results

Latest financial reports are more than 6 months old

My Notes

Capture your thoughts, links and company narrative

SYNLAB AG Competitors

Fresenius Medical Care

XTRA:FME

€12.9b

VITA 34

XTRA:V3V

€71.8m

RHÖN-KLINIKUM

XTRA:RHK

€923.8m

Carl Zeiss Meditec

XTRA:AFX

€4.0b

Price History & Performance

Summary of share price highs, lows and changes for SYNLAB
Historical stock prices
Current Share Price	€11.22
52 Week High	€11.70
52 Week Low	€10.66
Beta	0.89
1 Month Change	-1.75%
3 Month Change	5.25%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	1.81%

Recent updates

Shareholder Returns

	SYAB	DE Healthcare	DE Market
7D	-0.4%	-3.5%	-2.6%
1Y	n/a	15.6%	6.9%

Return vs Industry: Insufficient data to determine how SYAB performed against the German Healthcare industry.

Return vs Market: Insufficient data to determine how SYAB performed against the German Market.

Price Volatility

Is SYAB's price volatile compared to industry and market?
SYAB volatility
SYAB Average Weekly Movement	2.1%
Healthcare Industry Average Movement	4.7%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.2%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: SYAB has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine SYAB's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1998	27,000	Mathieu Floreani	www.synlab.com

SYNLAB AG provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. The company offers medical and veterinary diagnostics services. SYNLAB AG was founded in 1998 and is headquartered in Munich, Germany.

SYNLAB AG Fundamentals Summary

How do SYNLAB's earnings and revenue compare to its market cap?
SYAB fundamental statistics
Market cap	€2.47b
Earnings (TTM)	€89.35m
Revenue (TTM)	€2.62b

27.6x

P/E Ratio

0.9x

P/S Ratio

Is SYAB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SYAB income statement (TTM)
Revenue	€2.62b
Cost of Revenue	€604.92m
Gross Profit	€2.01b
Other Expenses	€1.92b
Earnings	€89.35m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.41
Gross Margin	76.87%
Net Profit Margin	3.42%
Debt/Equity Ratio	39.0%

How did SYAB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 06:26
End of Day Share Price	2024/12/20 00:00
Earnings	2024/03/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SYNLAB AG is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Blanka Porkolab	Barclays
Hassan Al-Wakeel	Barclays
Charlotte Friedrichs	Berenberg

SYNLAB HMSE:SYAB Stock Report